Campbell Alliance Sales Practice to Present at CBI's Leadership Summit on Evolving the Pharma S...(e.com target _new http://www.campbellal...)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Campbell Alliance Sales Practice to Present at CBI's Leadership Summit on Evolving the Pharma Sales Model
Date:9/5/2008
e.com" target="_new">http://www.campbellalliance.com.
CONTACT:
James Forte
Director, Public and Media Relations
Campbell Alliance
+1 919 844 7100, extension 7195
'/>"/>
| SOURCE Campbell Alliance Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Nader Naeymi-Rad Appointed Chief Operating Officer at Campbell Alliance
2. Darius Naigamwalla Appointed Senior Vice President and Head of the Brand Management Practice at Campbell Alliance
3. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
4. Campbell Alliance Clinical Development Practice to Conduct Two Workshops at 44th DIA Annual Meeting
5. Campbell Alliance Trade and Distribution Practice to Speak at CBIs Commercial Contracts and Chargeback Management Conference
6. Campbell Alliance Sales Practice to Present Workshop at SPBT Annual Conference
7. Campbell Alliance Clinical Development Practice to Present Session on Global EDC Rollout at Clinical Trials Congress, Europe
8. Campbell Alliance Adds Doug Linton, Former Cardinal Health Executive, to Executive Advisory Group
9. Campbell Alliance Managed Markets Practice to Take a Leadership Role at the CBI Forum on Effective Product Pricing and Modeling Strategies
10. Campbell Alliance Sales Practice to Conduct Workshop at EyeForPharma SFE Europe Conference
11. Campbell Alliance Brand Management and Managed Markets Practices to Speak at CBIs Early Commercialization Conference
Post Your Comments:
Breaking Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6Sirius Genomics Announces Change in Leadership 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 2Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 3Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea 4AEterna Zentaris Announces Appointment of New Board Member 2
[0] Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain[0] Sirius Genomics Announces Change in Leadership[0] Cumberland Pharmaceuticals Licenses Caldolor(R) (ibuprofen) Injection to DB Pharm Korea for Commercialization in South Korea[0] AEterna Zentaris Announces Appointment of New Board Member
Other Biology Technology:GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 2GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 3GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product 4Arpida Interim Results for six Months to 30 June 2007 2Arpida Interim Results for six Months to 30 June 2007 3Arpida Interim Results for six Months to 30 June 2007 4Arpida Interim Results for six Months to 30 June 2007 5Arpida Interim Results for six Months to 30 June 2007 6Arpida Interim Results for six Months to 30 June 2007 7Arpida Interim Results for six Months to 30 June 2007 8Arpida Interim Results for six Months to 30 June 2007 9Arpida Interim Results for six Months to 30 June 2007 10Processing Fees on ADRs to be Waived for two Months 2Processing Fees on ADRs to be Waived for two Months 3
Breaking Biology News(10 mins):Potential new heart attack biomarker uncovered 2From fruit fly wings to heart failure -- why Not(ch)? 2ESHRE announces its campus workshop: 'Artificial Insemination: An Update' 2APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009 Says Frost 26 Sullivan 50833 1APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009 Says Frost 26 Sullivan 50833 2APAC Sensors Market Likely to be Driven by Medical and Process Industries in 2009 Says Frost 26 Sullivan 50833 3Your own private global warming 9125 1Nano measurement in the third dimension 12903 1Nano measurement in the third dimension 12903 2
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |